Show results for
Refine by
Organs And Tissues For Transplantation Articles & Analysis
57 news found
The New York State Department of Health (NYSDOH) describes enterococci as part of the normal flora in the intestinal tract and also a common cause of nosocomial infections. The bacteria can also often found in the natural environment, in soil and water. The Centers for Disease Control and Prevention (CDC) warns these bacteria are constantly finding new ways to avoid the effects of the ...
At the same time, HLA plays a vital role in organ and bone marrow transplantation and is also associated with serious adverse reactions to different medications. Therefore, HLA typing is essential to the research of immune-related diseases, the screening of vaccine and drug target populations, the study of ethnic evolution, tissue, ...
$5.5M financing led by Taiho Ventures LLC, with participation of existing investors, including the Series Seed lead, Kizoo Technology Capital GmbH Fresh capital to be employed to get cellvie Series A ready by accelerating the development of the company's technology platform, strengthening the team, and advancing the mitochondria's GMP manufacturing cellvie Inc., a leader in Therapeutic ...
Shanghai, China and Rapperswil, Switzerland) Shanghai Fosun Pharma (Group) Co. (“Fosun Pharma”, stock code : 600196.SH; 02196.HK) announced that Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (“Fosun Pharmaceutical Industry”), a controlled subsidiary, signed an exclusive sales agency and development agreement with Switzerland ’s Neovii Pharmaceuticals ...
Neovii Pharmaceuticals AG (“Neovii”), a Swiss based global specialty-care biopharmaceutical company, and Shanghai Fosun Pharmaceutical Industry Development Co. Ltd (“Fosun Pharma Industry”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, Stock Code: 600196.SH, 02196.HK), a global pharmaceutical and healthcare industry group ...
As part of this grant, breast surgeon collaborators will use OnLume’s imaging device for intraoperative visualization and assessment of small lymphatic tissue and blood vessels. The FGS imaging system may help reduce the risk of two breast cancer-related morbidities, lymphedema and tissue necrosis. ...
Alume Bioscience’s CEO and founder Quyen Nguyen, MD/PhD, stated, “As surgeons, we rely on our experience to identify nerves, but often they are buried or appear indistinguishable from adjacent non-nerve tissue. This study aims to demonstrate improvement of surgical precision by making nerves ‘glow’ with fluorescence. ...
The OnLume Imaging System is indicated for fluorescence imaging of blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, reconstructive, and micro surgeries. ...
Phase 2 study completed enrollment ahead of schedule Posoleucel well-tolerated with no cases of graft rejection observed to date Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo (2:1 randomization) Posoleucel detected up to 12 weeks after last infusion Topline, unblinded study results from all 61 patients expected to be released ...
ByKalaris
Phase 1b Study of SER-155 in Stem Cell Transplant Hematopoietic stem cell transplant (HSCT) is frequently used to treat lymphoma, leukemia and multiple myeloma or for people who received high doses of chemotherapy or radiation that damaged their bone marrow. ...
(Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (HSCT) to avoid infection or Graft-versus-Host ...
” “In tandem, we are excited about our earlier stage pipeline and continue to enroll our Phase 1b clinical study of SER-155 designed to evaluate safety, microbiome alterations, and the impact on infections and/or graft versus host disease (GvHD) in adult subjects who are undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Preclinical activities ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. ...
This means that it can be dissolved in the body and absorbed into organs. The disease that Villix first targeted is ischemic reperfusion injury that occurs in organ transplant myocardial infarction, coronary artery bypass surgery, and stroke. ...
The computational approach performs HLA typing from next generation sequencing data by using the current strengths of conventional HLA typing while simultaneously allowing for the discovery of novel HLA alleles and tumor-specific HLA variants, through leveraging proprietary mutation calling bioinformatics at NOI. NOI collaborated with Ultimovacs ASA in the study to validate the HLA typing ...
Three ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies Expanded enrollment in Phase 2 proof-of-concept study of posoleucel for the preemptive treatment of BK viremia in kidney transplant recipients; initial data submitted for presentation in 1H 2022 Advancing two additional virus-specific T cell ...
ByKalaris
These are the start-ups that most impressed Britain’s top entrepreneurs and investors in 2019. There was a technology theme to the selections, while several on our panel of small business champions picked companies, they claimed were tackling some of the world’s biggest problems by treating Alzheimer’s disease and broadening access to education. ...
” In addition to the financing momentum, Prellis has recruited a pair of seasoned industry executives to support expansion of their EXIS platform: Kevin Chapman, PhD, formerly of Berkeley Lights, Inc. and Merck & Co., Inc., as Chief Scientific Officer Yelda Kaya, MBBS, LLB, MBA, formerly of J&J Innovation, GSK and Ashurst, as Chief Business Officer The EXIS platform ...
” In addition to the financing momentum, Prellis has recruited a pair of seasoned industry executives to support expansion of their EXIS platform: Kevin Chapman, PhD, formerly of Berkeley Lights, Inc. and Merck & Co., Inc., as Chief Scientific Officer Yelda Kaya, MBBS, LLB, MBA, formerly of J&J Innovation, GSK and Ashurst, as Chief Business Officer The EXIS platform ...
In the case described above, the patient did not take long-term immuno-suppression therapy. With typical organ transplants, immuno-suppressive drugs are required to prevent the patient's immune system from rejecting the donated organ. ...